|Description||GSK-554418A is a azaindole Cannabinoid receptor type 2 (CB2) agonist. It can be used for the treatment of chronic pain.|
|Synonyms||GSK-554418A; GSK 554418A; GSK554418A . (4-((3-chlorophenyl)amino)-1-methyl-1H-pyrrolo(3,2-C)pyridin-7-yl)-4-morpholinyl- Methanone|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
BAY 38-7271, also called as KN 38-7271, is a cannabinoid receptor agonist with analgesic and neuroprotective effects. The doses of BAY 38-7271 in animals needed...
Levonantrado is a synthetic cannabinoid analog of dronabinol developed by Pfizer in the 1980s. Levonantrado is around 30x more potent than THC, and exhibits ant...
Jd-5037 is a peripherally-restricted cannabinoid inverse agonist at CB1 receptors that can be used as an anti-obesity drug, with a 700-fold higher affinity comp...
(R)-(+)-SLV 319 is a less active enantiomer of SLV 319, which is a central cannabinoid (CB1) receptor antagonist. SLV 319 has the potential to treat neuroinflam...
AM 1172, an AEA analogue, has been found to be an anandamide uptake inhibitor as well as a cannabinoid receptor partial agonist.
AM251 block the inhibitory effects of endocannabinoids and synthetic cannabinoid agonists on transmitter release through an action at presynaptic cannabinoid 1 ...
COR 170 has been found to be an inverse agonist of CB2 receptors and could be used in studies for CB1 and CB2 receptor affinity.
AM 1235, a synthetic cannabimimetic indole derivative, is a potent and selective agonist for the cannabinoid receptor, with Ki values of 1.5 and 20.4 nM for the...